Merck and Eli Lilly to Report Q3 Earnings October 29

Healthcare operators should watch for shifts in pharmacy purchasing and competition as these major firms report quarterly results.

Updated on Oct. 28, 2026 in Healthcare

Bold flat-color editorial illustration of medical vials in black, cream, and red, representing the pharmaceutical industry's market analysis. — Merck and Eli Lilly are scheduled to report third-quarter earnings on October 29, with analysts projecting pressure from market competition and patent expirations. AI Illustration. Upload story photo >

Live Poll

Will Merck and Eli Lilly report higher-than-projected earnings for the third quarter of 2026?

Merck and Eli Lilly are set to report their third-quarter earnings on October 29, 2026, with analysts anticipating declines for both pharmaceutical giants. These results will highlight the evolving pressures facing the industry, including patent expirations for Merck and intense competition in the weight-loss drug market for Eli Lilly.

Why it matters

Operators in the healthcare sector should monitor these results as indicators of broader shifts in specialty pharmacy purchasing and drug pricing. These findings reflect how established pharmaceutical companies are navigating the transition between legacy product reliance and newer, high-growth franchises.

Analysts project a 19% decline in Merck's earnings per share, setting a $2.09 per share target for the third quarter. While Eli Lilly's revenue trajectory remains tied to its obesity franchise, the extent of pricing pressure from increased competition in the GLP-1 sector remains under evaluation.

The players

Merck

A global pharmaceutical company managing a major portfolio of oncology products while navigating significant patent-related revenue challenges.

Eli Lilly

A pharmaceutical developer focused on high-growth metabolic and weight-loss treatments within a highly competitive market.

The details

Merck faces a complex operational environment defined by an approaching patent cliff and slowing sales growth for its core Keytruda product, compounded by structural changes in how specialty pharmacies purchase medications. Conversely, Eli Lilly's performance hinges on maintaining market share for Mounjaro and Zepbound, where intensifying competition is creating significant pricing volatility in the obesity and weight-loss segments.

October 29, 2026: Merck and Eli Lilly release third-quarter results.

Market Landscape

This reporting cycle emphasizes the industry-wide challenge of managing the pharmaceutical patent cliff alongside rapid shifts in high-growth therapeutic markets. It reflects a standard cyclical pressure for large-cap firms that must balance expiring legacy exclusivity against intense competition for new drug categories.

Healthcare operators should track how Merck's specialty pharmacy purchasing changes set new pricing benchmarks that may trickle down to smaller providers. Watch Eli Lilly's competitive posture in the GLP-1 market as a key indicator of margin health for those involved in pharmacy and drug distribution.

The takeaway

Large pharmaceutical earnings provide a signal on the strength of the broader drug distribution and purchasing environment. Operators should review these disclosures to assess how upcoming patent transitions and competitive pricing shifts may impact their own supply chain costs in the next fiscal year.